Immune response to enzyme replacement therapy in Fabry disease: Impact on clinical outcome?
- 31 January 2009
- journal article
- editorial
- Published by Elsevier BV in Molecular Genetics and Metabolism
- Vol. 96 (1), 1-3
- https://doi.org/10.1016/j.ymgme.2008.10.013
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry diseaseMolecular Genetics and Metabolism, 2009
- Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry RegistryMolecular Genetics and Metabolism, 2008
- Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry DiseaseAmerican Journal of Human Genetics, 2004
- Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome SurveyEuropean Journal of Clinical Investigation, 2004
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier femalesJournal of Medical Genetics, 2001
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's DiseaseThe New England Journal of Medicine, 2001
- Enzyme Replacement Therapy in Fabry DiseaseJama-Journal Of The American Medical Association, 2001
- Individualised low-dose alglucerase therapy for type 1 Gaucher's diseaseThe Lancet, 1995
- Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 monthsBlood, 1993
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseThe New England Journal of Medicine, 1991